Medicare AdvantageCoverageMedium impact
MA11.116a, Laparoscopic, Percutaneous, and Transcervical Techniques for Uterine Fibroid Myolysis
Independence Blue Cross·OB-GYN·Medical Policy
Effective date
Jun 24, 2026
We identified it
Jun 25, 2026
Summary
Medicare Advantage policy MA11.116a regarding laparoscopic, percutaneous, and transcervical techniques for uterine fibroid myolysis has been reissued effective June 24, 2026. This is a policy reissue with updated guidance on coverage and billing requirements for these fibroid treatment modalities. The billing team must review the full policy details to identify any changes to coverage criteria, prior authorization requirements, or affected procedure codes.
Action Required
By June 24, 2026: Billing team must access the full policy text at the provided URL (https://medpolicy.ibx.com/ibc/ma/Pages/Site-Activity-View.aspx) to review complete details of MA11.116a. Identify any changes to: (1) covered vs. non-covered procedures for fibroid myolysis, (2) prior authorization requirements, (3) affected CPT/HCPCS codes, and (4) documentation requirements. Update billing system rules, encounter forms, and provider guidelines accordingly. Alert OB-GYN providers of any coverage or authorization changes. Failure to implement changes by the effective date may result in claim denials or rejections for fibroid treatment procedures.